27 November 2016
As the U.S. races to legalize marijuana for medicinal and recreational use, a new, large scale brain imaging study gives reason for caution. Published in the Journal of Alzheimer’s Disease, researchers using single photon emission computed tomography (SPECT), a sophisticated imaging study that evaluates blood flow and activity patterns, demonstrated abnormally low blood flow in virtually every area of the brain studies in nearly 1,000 marijuana compared to healthy controls, including areas known to be affected by Alzheimer’s pathology such as the hippocampus.
23 November 2016
A new study from The University of Texas Medical Branch at Galveston offers important insight into how Alzheimer’s disease begins within the brain. The researchers found a relationship between inflammation, a toxic protein and the onset of the disease. The study also identified a way that doctors can detect early signs of Alzheimer’s by looking at the back of patients’ eyes.
20 November 2016
Aurin Biotech announced today that it has developed a simple saliva test that can diagnose Alzheimer's disease, as well as predict its future onset, allowing individuals to take preventive measures before the disease takes hold. The disease, which affects an estimated 35 million people worldwide, is predicted to double in 20 years if progress is not made. In addition, the current cost of caring for Alzheimer's patients is estimated at more than $500 billion per year.
1 November 2016
Greek researchers demonstrated the potential use of assistive technologies for people with dementia, to fulfill an important need: the improvement of clinical diagnosis and decision making meeting individual needs. Remote home monitoring of patients is a promising “participant-centered” management approach which provides relevant and reliable information that enables clinicians to drive adaptive interventions.
22 September 2016
Study Demonstrates Mass Spectrometry Technique Dramatically Enhances Detection of Key Early Stage Alzheimer’s Biomarkers
A peer reviewed study led by Proteome Sciences plc (“Proteome Sciences”), in conjunction with a group of highly respected universities and hospitals, demonstrates the ability of an innovative mass spectrometry workflow to dramatically improve the ability to detect tau-derived peptides that are directly related to human Alzheimer’s pathology as early stage biomarkers of the disease. Published on-line in the Journal of Alzheimer’s Disease, the study describes the application of the workflow, TMTcalibrator, for high-sensitivity detection of phosphorylated tau and other disease-relevant biomarkers of Alzheimer’s disease in cerebrospinal fluid.
14 September 2016
A new study led by Laurent Meijer, at ManRos Therapeutics, and collaborators shows that some herbicides (triazines) trigger enhanced in vitro production of the Aβ42 over Aβ40 amyloid peptides in various cell lines. This suggests that some products from the ‘human chemical exposome’ (HCE) (estimated to be over 85,000 products) may contribute to the increased production of Aβ42 over Aβ40 characteristic of Alzheimer’s disease (AD). In addition, some of these products might be turned into pharmacological tools to develop a chemically-induced animal model of AD (in contrast with the currently used genetic, recombinant mice models).
13 September 2016
New UBC research finds that many online resources for preventing Alzheimer’s disease are problematic and could be steering people in the wrong direction. In a survey of online articles about preventing Alzheimer’s disease, UBC researchers found many websites offered poor advice and one in five promoted products for sale—a clear conflict of interest.
9 September 2016
Efficacy and Safety of Crocus Sativus L in Patients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial
Greek researchers and clinicians demonstrated the potential of Crocus Sativus L. (saffron) as a therapeutic pharmaceutical natural compound for older adults with amnestic Mild Cognitive Impairment (aMCI). MCI is a condition that often predates Alzheimer’s disease (AD) and is characterized by memory loss and inability to execute complex Activities of Daily Living. While there is no treatment for MCI and symptomatic only treatment for AD, the global effort against cognitive disorders is focused on early detection and management of AD at the stage of MCI.
9 September 2016
A long-term follow-up study of 3050 twins from the Finnish Twin Cohort has shown that midlife, moderately vigorous physical activity is associated with better cognition at old age. The association was statistically independent of midlife hypertension, smoking, education level, sex, obesity and binge drinking. This suggests that the beneficial influence of physical activity on the brain and cognition is not solely based on decreasing vascular risk factors.
7 September 2016
Markers associated with Alzheimer’s and Parkinson’s diseases are present in Mexico City children chronically exposed to concentrations of fine particulate matter PM2.5 above the current EPA USA standards
A new study by researchers at the Universities of Montana, Valle de México, Boise State, Veracruz University, Médica Sur, Centro de Ciencias de la Atmósfera, UNAM, Hospital Regional de Alta Especialidad, Ciudad Victoria, Hospital de Especialidades #14, IMSS, Centre Hospitalier Universitaire, Hôpital de Hautepierre and AJ Roboscreen GmbH heightens concerns over the detrimental impact of fine particulate matter PM2.5 on CSF markers associated with Alzheimer and Parkinson’s diseases in children ages 11.9±4.8 years. These findings are published in the Journal of Alzheimer’s Disease.